RUBY - Rubius Therapeutics, Inc.
| Previous Close | 17.27 |
| Open | 17.26 |
| Bid | 0.00 x 800 |
| Ask | 19.70 x 900 |
| Day's Range | 16.94 - 18.84 |
| 52 Week Range | 2.71 - 33.01 |
| Volume | 40,235 |
| Avg. Volume | 307,476 |
| Market Cap | 1.467B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.67 |
- ACCESSWIRE•23 days ago
Biotech Market is Rolling and These Companies Need to Be on Your Radar
HENDERSON, NV / ACCESSWIRE / September 24, 2018 / Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, some investors may feel like they missed out. Don't ...
- Zacks•23 days ago
Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- GlobeNewswire•27 days ago
Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
CAMBRIDGE, Mass., Sept. 20, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, ...
- GlobeNewswire•last month
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes
CAMBRIDGE, Mass., Sept. 14, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that the company will ...
- Investor's Business Daily•last month
How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease
Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.
- GlobeNewswire•last month
Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 04, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, ...
- GlobeNewswire•2 months ago
Rubius Therapeutics Reports Second Quarter 2018 Financial Results
CAMBRIDGE, Mass., Aug. 31, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today reported second quarter 2018 financial ...
- GlobeNewswire•2 months ago
Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
CAMBRIDGE, Mass., Aug. 21, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, plans to report second quarter 2018 financial ...
- GlobeNewswire•3 months ago
Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics
Rubius Therapeutics, Inc. (RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island. “The acquisition of the Rhode Island manufacturing facility is a critical step toward making the promise of Red Cell Therapeutics a reality,” said Pablo J. Cagnoni, M.D., Chief Executive Officer of Rubius. “We believe that by owning our manufacturing capabilities and controlling our supply chain we will be prepared to scale up manufacturing of clinical and potentially commercial supply of our novel therapies.
- The Wall Street Journal•3 months ago
[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech
Public-market investors’ embrace of health-care startups is extending beyond biotechnology to medical-technology companies. Twenty-nine venture-backed health-care startups went public in the first half, equaling the 2017 yearly total, according to market tracker Dow Jones VentureSource. Biotech had 26 IPOs in the first half of 2018 and 25 in all of 2017, according to VentureSource.
- GlobeNewswire•3 months ago
Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., July 23, 2018-- Rubius Therapeutics, Inc., a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced the closing of its initial ...
- The Wall Street Journal•3 months ago
[$$] Gormley's Take: Biotech Would-Be Acquirers Are Wary Buyers
Biotech mergers and acquisitions are cooling down as much as initial public offerings in the sector are heating up. Twenty-six venture-backed biotechs went public in the first half, one more than in all of 2017, according to Dow Jones VentureSource. Inc., which is valued at nearly $2 billion following its Wednesday IPO.
